CDT Biomarker Detection for IBS Differential Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating irritable bowel syndrome (IBS) focus on symptom relief rather than addressing the underlying cause, and there is a lack of effective biomarkers to distinguish IBS from other gastrointestinal disorders like inflammatory bowel disease (IBD) and celiac disease, leading to inefficient diagnosis and treatment.
Innovation Solution
A method involving the detection of cytolethal distending toxin (CDT) or its markers in biological samples to diagnose IBS, differentiate it from other conditions, and determine the likelihood of developing IBS or responding to antibiotic treatment, using specific antibodies and immune responses to CDT subunits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then diagnosis can be performed, but diagnostic precision is insufficient to distinguish IBS from other gastrointestinal disorders
Solution Approach 1:
The patent segments the diagnostic process by introducing specific biomarker detection (anti-CdtB antibodies, CDT subunit detection) to differentiate IBS from other gastrointestinal disorders. This segmentation allows clinicians to distinguish IBS cases from IBD, celiac disease, and other conditions through targeted biomarker analysis, thereby improving diagnostic precision without requiring broad, less specific testing methods.
2Reliability
If symptom-based treatment is used, then treatment can be provided, but treatment effectiveness is limited due to lack of targeted therapy
Solution Approach 1:
The patent applies preliminary action by detecting CDT markers and anti-CdtB antibodies before treatment initiation. This pre-treatment biomarker assessment allows clinicians to identify patients who will respond to antibiotic therapy versus those who won't, enabling targeted treatment selection in advance. This preliminary diagnostic step increases treatment effectiveness by avoiding ineffective treatments while the standardized biomarker testing simplifies rather than complicates the overall treatment decision process.
3Measurement precision
If broad diagnostic testing is performed, then various conditions can be ruled out, but diagnostic time and cost increase
Solution Approach 1:
The patent extracts the essential diagnostic function by focusing on specific, high-value biomarkers (anti-CdtB antibodies, CDT subunits) that directly differentiate IBS from other gastrointestinal disorders. Rather than performing comprehensive broad-spectrum testing, this extraction approach isolates the most discriminatory markers, enabling rapid differentiation of IBS cases from mimics like IBD and celiac disease, thereby reducing diagnostic time while maintaining high accuracy for the target condition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for more accurate diagnosis and targeted treatment of IBS by identifying CDT presence or absence, correlating with IBS likelihood and treatment response, thereby improving patient outcomes and reducing diagnostic morbidity.
Implementation Method 1
detecting the presence or absence of cytolethal distending toxin (CDT) or one or more markers of CDT... using specific antibodies and immune responses to CDT subunits
Data Source
AI summary
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.